Connor Clark & Lunn Investment Management Ltd. Raises Stake in Catalyst Pharmaceuticals Inc (CPRX)

Connor Clark & Lunn Investment Management Ltd. increased its stake in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) by 18.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,700 shares of the biopharmaceutical company’s stock after purchasing an additional 5,688 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Catalyst Pharmaceuticals were worth $70,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Meeder Asset Management Inc. boosted its stake in Catalyst Pharmaceuticals by 185.1% in the 4th quarter. Meeder Asset Management Inc. now owns 34,237 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 22,227 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its stake in Catalyst Pharmaceuticals by 152.9% in the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 42,900 shares of the biopharmaceutical company’s stock worth $162,000 after purchasing an additional 25,940 shares in the last quarter. MetLife Investment Advisors LLC boosted its stake in Catalyst Pharmaceuticals by 38.1% in the 3rd quarter. MetLife Investment Advisors LLC now owns 69,540 shares of the biopharmaceutical company’s stock worth $263,000 after purchasing an additional 19,191 shares in the last quarter. Virtu Financial LLC acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at approximately $201,000. Finally, Rhumbline Advisers lifted its stake in Catalyst Pharmaceuticals by 49.9% during the 4th quarter. Rhumbline Advisers now owns 126,699 shares of the biopharmaceutical company’s stock valued at $243,000 after acquiring an additional 42,199 shares during the period. Institutional investors own 47.83% of the company’s stock.

Several brokerages have commented on CPRX. ValuEngine cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 1st. Cantor Fitzgerald restated a “buy” rating and set a $10.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Tuesday, March 19th. BidaskClub upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, March 27th. Finally, Zacks Investment Research cut shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, February 13th. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $6.55.

NASDAQ CPRX traded up $0.14 on Monday, hitting $5.53. The company had a trading volume of 923,600 shares, compared to its average volume of 1,575,790. The firm has a market cap of $553.77 million, a PE ratio of -16.76 and a beta of 2.43. Catalyst Pharmaceuticals Inc has a 12-month low of $1.85 and a 12-month high of $5.68.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The company had revenue of $0.50 million for the quarter. As a group, research analysts predict that Catalyst Pharmaceuticals Inc will post -0.22 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Connor Clark & Lunn Investment Management Ltd. Raises Stake in Catalyst Pharmaceuticals Inc (CPRX)” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/15/connor-clark-lunn-investment-management-ltd-has-70000-holdings-in-catalyst-pharmaceuticals-inc-cprx.html.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

See Also: How to Use a Moving Average for Trading 

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.